ResMed Q1 2025 Adj. EPS $2.20 Beats $2.04 Estimate, Sales $1.224B Beat $1.180B Estimate
Portfolio Pulse from Benzinga Newsdesk
ResMed reported Q1 2025 earnings per share of $2.20, surpassing the analyst estimate of $2.04. The company's sales reached $1.224 billion, exceeding the expected $1.180 billion and marking an 11.12% increase from the previous year.
October 24, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ResMed's Q1 2025 earnings and sales exceeded analyst expectations, with EPS at $2.20 and sales at $1.224 billion, indicating strong financial performance.
ResMed's earnings per share and sales both exceeded analyst expectations, which is typically a positive indicator for stock performance. The significant year-over-year sales growth further supports a positive outlook.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100